title: Safety of besifloxacin ophthalmic suspension 0.6% in cataract surgery patients.
authors.forename: Jai G
authors.initials: JG
authors.lastname: Parekh
authors.forename: T Hunter
authors.initials: TH
authors.lastname: Newsom
authors.forename: Steven
authors.initials: S
authors.lastname: Nielsen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis / Q000009:adverse effects*; D001372:Aza Compounds / Q000009:adverse effects / Q000627:therapeutic use; D001381:Azepines / Q000009:adverse effects* / Q000627:therapeutic use; D015818:Eye Infections, Bacterial / Q000517:prevention & control*; D005260:Female; D024841:Fluoroquinolones / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D019654:Lens Implantation, Intraocular; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D009883:Ophthalmic Solutions / Q000009:adverse effects / Q000627:therapeutic use; D018918:Phacoemulsification; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies
chemical_list: D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D001381:Azepines; D024841:Fluoroquinolones; D009883:Ophthalmic Solutions; D011804:Quinolines; C522124:besifloxacin; D000077266:Moxifloxacin